Detalhe da pesquisa
1.
Chronic inflammation decreases HSC fitness by activating the druggable Jak/Stat3 signaling pathway.
EMBO Rep
; 24(1): e54729, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341527
2.
PEGylated Molybdenum-Iodine Nanocluster as a Promising Radiodynamic Agent against Prostatic Adenocarcinoma.
Inorg Chem
; 63(9): 4419-4428, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364266
3.
Design, synthesis, and in vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition.
J Enzyme Inhib Med Chem
; 36(1): 410-424, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33440995
4.
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.
Haematologica
; 105(7): 1868-1878, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582537
5.
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells.
Mol Med Rep
; 27(4)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36825563
6.
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.
Cell Death Dis
; 14(3): 209, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964168
7.
Avenue to X-ray-induced photodynamic therapy of prostatic carcinoma with octahedral molybdenum cluster nanoparticles.
J Mater Chem B
; 10(17): 3303-3310, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380154
8.
Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics.
Front Aging Neurosci
; 14: 1048260, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36561137
9.
Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
Int J Cancer
; 126(12): 2997-3004, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19739073
10.
Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Int J Oncol
; 53(5): 1997-2009, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30226595
11.
The role of immune cell subpopulations in the growth and rejection of TC-1/A9 tumors in novel mouse strains differing in the H2-D haplotype and NKC domain.
Oncol Lett
; 15(3): 3594-3601, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467880
12.
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.
Oncoimmunology
; 6(12): e1362528, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29209567
13.
Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors.
Int J Oncol
; 49(2): 763-72, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27279019
14.
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
Oncotarget
; 7(34): 54952-54964, 2016 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27448982
15.
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Int J Oncol
; 48(3): 953-64, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26718011
16.
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Int J Oncol
; 26(2): 521-7, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15645139
17.
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Int J Oncol
; 25(4): 1165-70, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15375569
18.
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Int J Oncol
; 24(1): 161-7, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14654953
19.
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Int J Oncol
; 22(3): 691-5, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12579325
20.
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Int J Oncol
; 20(3): 643-6, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11836582